Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.54 |
| ▸ | UBE2M | P61081 | 6/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.53 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865905 | 1.00 | EPHX2 (0.55) | EPHX2DCUN1D1UBE2MGSK3AGSK3B | |
| SCHEMBL6866315 | 0.90 | KDM4E (0.58) | EPHX2GSK3AGSK3BKMT5BKMT5C | |
| SCHEMBL6866318 | 0.90 | KDM4E (0.58) | EPHX2GSK3AGSK3BKMT5BKMT5C | |
| SCHEMBL6861487 | 0.90 | KMT5B (0.60) | EPHX2GSK3AGSK3BKMT5BKMT5C | |
| SCHEMBL6861493 | 0.90 | KMT5B (0.60) | EPHX2GSK3AGSK3BKMT5BKMT5C | |
| SCHEMBL6861694 | 0.88 | KMT5B (0.62) | GSK3AGSK3BKMT5BKMT5CNTRK1 | |
| SCHEMBL6861684 | 0.88 | KMT5B (0.62) | GSK3AGSK3BKMT5BKMT5CNTRK1 | |
| SCHEMBL6871768 | 0.87 | TRPV1 (0.53) | EPHX2DCUN1D1UBE2MGSK3AGSK3B | |
| SCHEMBL6871773 | 0.87 | TRPV1 (0.53) | EPHX2DCUN1D1UBE2MGSK3AGSK3B | |
| SCHEMBL6869985 | 0.86 | KMT5B (0.55) | EPHX2GSK3AGSK3BKMT5BKMT5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | claimed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | claimed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | EPHX2 4027/4885DCUN1D1 1404/4885UBE2M 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.